Cargando…

CD34 positive cells as endothelial progenitor cells in biology and medicine

CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known to be rich sources of EPCs. Therefore, regenerative therapy using CD34(+) cells has attracted interest for application in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassanpour, Mehdi, Salybekov, Amankeldi A., Kobayashi, Shuzo, Asahara, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150654/
https://www.ncbi.nlm.nih.gov/pubmed/37138792
http://dx.doi.org/10.3389/fcell.2023.1128134
_version_ 1785035394123825152
author Hassanpour, Mehdi
Salybekov, Amankeldi A.
Kobayashi, Shuzo
Asahara, Takayuki
author_facet Hassanpour, Mehdi
Salybekov, Amankeldi A.
Kobayashi, Shuzo
Asahara, Takayuki
author_sort Hassanpour, Mehdi
collection PubMed
description CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known to be rich sources of EPCs. Therefore, regenerative therapy using CD34(+) cells has attracted interest for application in patients with various vascular, ischemic, and inflammatory diseases. CD34(+) cells have recently been reported to improve therapeutic angiogenesis in a variety of diseases. Mechanistically, CD34(+) cells are involved in both direct incorporation into the expanding vasculature and paracrine activity through angiogenesis, anti-inflammatory, immunomodulatory, and anti-apoptosis/fibrosis roles, which support the developing microvasculature. Preclinical, pilot, and clinical trials have well documented a track record of safety, practicality, and validity of CD34(+) cell therapy in various diseases. However, the clinical application of CD34(+) cell therapy has triggered scientific debates and controversies in last decade. This review covers all preexisting scientific literature and prepares an overview of the comprehensive biology of CD34(+) cells as well as the preclinical/clinical details of CD34(+) cell therapy for regenerative medicine.
format Online
Article
Text
id pubmed-10150654
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101506542023-05-02 CD34 positive cells as endothelial progenitor cells in biology and medicine Hassanpour, Mehdi Salybekov, Amankeldi A. Kobayashi, Shuzo Asahara, Takayuki Front Cell Dev Biol Cell and Developmental Biology CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known to be rich sources of EPCs. Therefore, regenerative therapy using CD34(+) cells has attracted interest for application in patients with various vascular, ischemic, and inflammatory diseases. CD34(+) cells have recently been reported to improve therapeutic angiogenesis in a variety of diseases. Mechanistically, CD34(+) cells are involved in both direct incorporation into the expanding vasculature and paracrine activity through angiogenesis, anti-inflammatory, immunomodulatory, and anti-apoptosis/fibrosis roles, which support the developing microvasculature. Preclinical, pilot, and clinical trials have well documented a track record of safety, practicality, and validity of CD34(+) cell therapy in various diseases. However, the clinical application of CD34(+) cell therapy has triggered scientific debates and controversies in last decade. This review covers all preexisting scientific literature and prepares an overview of the comprehensive biology of CD34(+) cells as well as the preclinical/clinical details of CD34(+) cell therapy for regenerative medicine. Frontiers Media S.A. 2023-04-17 /pmc/articles/PMC10150654/ /pubmed/37138792 http://dx.doi.org/10.3389/fcell.2023.1128134 Text en Copyright © 2023 Hassanpour, Salybekov, Kobayashi and Asahara. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Hassanpour, Mehdi
Salybekov, Amankeldi A.
Kobayashi, Shuzo
Asahara, Takayuki
CD34 positive cells as endothelial progenitor cells in biology and medicine
title CD34 positive cells as endothelial progenitor cells in biology and medicine
title_full CD34 positive cells as endothelial progenitor cells in biology and medicine
title_fullStr CD34 positive cells as endothelial progenitor cells in biology and medicine
title_full_unstemmed CD34 positive cells as endothelial progenitor cells in biology and medicine
title_short CD34 positive cells as endothelial progenitor cells in biology and medicine
title_sort cd34 positive cells as endothelial progenitor cells in biology and medicine
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150654/
https://www.ncbi.nlm.nih.gov/pubmed/37138792
http://dx.doi.org/10.3389/fcell.2023.1128134
work_keys_str_mv AT hassanpourmehdi cd34positivecellsasendothelialprogenitorcellsinbiologyandmedicine
AT salybekovamankeldia cd34positivecellsasendothelialprogenitorcellsinbiologyandmedicine
AT kobayashishuzo cd34positivecellsasendothelialprogenitorcellsinbiologyandmedicine
AT asaharatakayuki cd34positivecellsasendothelialprogenitorcellsinbiologyandmedicine